Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 92.28 USD -0.38% Market Closed
Market Cap: 114.9B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Gilead Sciences Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gilead Sciences Inc
Cost of Revenue Peer Comparison

Comparables:
ABBV
AMGN
ALNY
VRTX
REGN

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.3B
CAGR 3-Years
-5%
CAGR 5-Years
-7%
CAGR 10-Years
-6%
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.2B
CAGR 3-Years
-1%
CAGR 5-Years
-19%
CAGR 10-Years
-15%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$12.9B
CAGR 3-Years
-27%
CAGR 5-Years
-25%
CAGR 10-Years
-13%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Cost of Revenue
-$306.4m
CAGR 3-Years
-35%
CAGR 5-Years
-84%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.5B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
0%
CAGR 5-Years
-22%
CAGR 10-Years
-25%

See Also

What is Gilead Sciences Inc's Cost of Revenue?
Cost of Revenue
-6.3B USD

Based on the financial report for Sep 30, 2024, Gilead Sciences Inc's Cost of Revenue amounts to -6.3B USD.

What is Gilead Sciences Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-6%

Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for Gilead Sciences Inc have been -5% over the past three years , -7% over the past five years , and -6% over the past ten years .

Back to Top